Technology Platform
Research

Harnessing Biology for Faster Recovery


Our Research
starts with Science

At Tiger Wound Care, every advanced biological wound care technology we offer begins with science. Our research drives the development of tissue-based technologies for wound care, ensuring that each product is rooted in a deep understanding of the biological and structural factors essential for the body’s own recovery.


Understanding
the Extracellular
Matrix (ECM)

A central focus of our work is the Extracellular Matrix (ECM), a dynamic network of proteins (including collagen, elastin, proteoglycans) that forms the structural and functional foundation of healthy tissue.

By studying the ECM’s composition and architecture, our scientists identify the factors that influence tissue integrity and their ability to support cellular regeneration.

This knowledge guides us in refining our products to better simulate the natural tissue environment.

Harnessing Naturally
Occurring Growth
Factors

Equally important is our investigation of naturally occurring growth factors, biomolecules essential for cellular proliferation, migration, tissue remodeling, and vascularization.

Through laboratory investigations, we assess how to preserve and optimize these factors within our tissue-based products.

By maintaining the native biochemical signals that guide wound repair, we aim to accelerate the patient’s own ability to recover.


Driving Continuous
Innovation

Each step in our research process is designed to translate scientific findings into tangible benefits for wound care.

We continually assess new data, refine processing techniques, and collaborate with clinical partners to ensure our solutions align with evolving healthcare needs.

In doing so, we integrate the latest science into every aspect of our advanced biological wound care tehnologies, always with a focus on supporting better patient outcomes.

Overview of ongoing RCTs

Currently, Tiger Wound Care is conducting ongoing randomized controlled trials (RCT) to evaluate the effectiveness of our CAMPs technologies.

One of our current trials is a 12-week, IRB-approved study that is enrolling up to 340 patients across 20 clinical sites in the United States and is currently in the enrollment phase.

Details can be found at clinicaltrials.gov and, once concluded, more information will be provided.